Related Experiment Video
Updated: May 21, 2026

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
Published on: March 8, 2018
Risks and untoward toxicities of antibody-based immunoconjugates
Dana Litvak-Greenfeld1, Itai Benhar
1Department of Molecular Microbiology and Biotechnology, The George S. Wise Faculty of Life Sciences, Tel-Aviv University, Ramat Aviv 69978, Israel.
Antibody immunoconjugates deliver potent cytotoxic agents for enhanced therapy. Careful design is crucial to balance therapeutic effectiveness with manageable toxicity profiles for these advanced treatments.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- Antibody-based immunoconjugates link monoclonal antibodies with cytotoxic payloads.
- These include antibody-drug conjugates, radioimmunoconjugates, and immunotoxins.
- They offer enhanced efficacy compared to unconjugated antibodies.
Purpose of the Study:
- To review the toxicities associated with potent agents used in antibody immunoconjugates.
- To highlight the importance of careful molecular design for safety and efficacy.
Main Methods:
- Literature review of antibody immunoconjugate therapies.
- Analysis of toxicity profiles and safety considerations.
- Discussion of design strategies for therapeutic effectiveness.
Main Results:
- Antibody immunoconjugates demonstrate significant therapeutic potential.
- The potent cytotoxic payloads necessitate careful safety assessments.
- Toxicity remains a key concern requiring meticulous design.
Conclusions:
- Antibody immunoconjugates represent a promising therapeutic strategy.
- Balancing efficacy and safety is paramount for clinical success.
- Further research into mitigating toxicity is essential.
Related Concept Videos
Drug Toxicity: Allergic Reactions
Drug Toxicity: Risk factors
Cross-reactivity
Humoral Immune Responses
Drug Toxicity: Overview
Drug toxicity: Idiosyncratic Reactions
